Announcements Trials
Browse Landscape

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 13Observational 2Expanded_access 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Carcinoma, Hepatocellular 18Cholangiocarcinoma 3Thyroid Neoplasms 2Recurrence 1Neoplasms, Glandular and Epithelial 1Neoplasms 1Liver Neoplasms 1Liver Diseases 1Coitus 1Carcinoma, Renal Cell 1Carcinoma 1Biliary Tract Neoplasms 1

Interventions

Thyroidectomy 5Iodine-131 5Surgical Procedures, Operative 3selpercatinib 2lenvatinib 2anlotinib 2Ultrasonography 2Transurethral Resection of Prostate 2Sorafenib 2Molecular Diagnostic Techniques 2Interviews as Topic 2Focus Groups 2Biopsy, Fine-Needle 2trastuzumab deruxtecan 1trametinib 1pralsetinib 1pembrolizumab 1gallium Ga 68 dotatate 1dabrafenib 1Triiodothyronine 1Thyroxine 1Thyrotropin Alfa 1Surveys and Questionnaires 1Routinely Collected Health Data 1Radiotherapy, Adjuvant 1Quality of Life 1Patient Reported Outcome Measures 1Observation 1Nivolumab 1Minimally Invasive Surgical Procedures 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × Thyroid Neoplasms × lenvatinib × Clear all
NCT07419932 2026-02-19

NeoLATC

Fujian Medical University

Recruiting
120 enrolled
Head & Neck

Thyroid Neoplasms

NCT02430714 2020-01-09

Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)

Eisai Inc.

Completed
629 enrolled
Head & Neck

Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡